Jan. 9, 2020
On December 20th, 2019, a magistrate judge recommended in a preliminary report that 2 out of the 4 claims in CareDx’s false advertising suit against Natera be dismissed. The magistrate’s recommendation is based on the sufficiency of the pleadings, rather than on the merits of any claim. We are pleased with this outcome and we look forward to prevailing on any remaining claims, should the case make it to trial.
Despite CareDx’s repeated attempts to discredit the performance capabilities of the Prospera test — which has been clinically and analytically validated by scientific, peer-reviewed evidence — we believe that we will prevail in this suit and that CareDx’s meritless claims against Natera will not disrupt the launch of Prospera and our mission to support improved patient care.